Preparation and application of TRAb

By providing recombinant antibodies with specific amino acid sequences and magnetic microparticle chemiluminescence methods, the rapid and sensitivity problems of TRAb detection in the prior art are solved, and efficient diagnosis and prognosis judgment of thyroid disease are achieved.

CN118909122APending Publication Date: 2024-11-08ZHENGZHOU IMMUNO BIOTECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411165748.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to quickly and sensitively detect the concentration of thyrotropin receptor antibodies (TRAbs) in patients' serum, affecting the diagnosis and prognosis of thyroid diseases.

Method used

A recombinant antibody is provided, and its heavy and light chain variable regions have specific amino acid sequences. The TSHR recombinant murine monoclonal antibody obtained by screening through hybridoma screening technology is used to detect TRAbs and achieve high quality in combination with magnetic microparticle chemiluminescence method. Sensitivity and specificity.

Benefits of technology

It realizes rapid and sensitive detection of TRAb, with high consistency between the test results and liquid quality results, good stability of repeated detection, and has important clinical diagnostic value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to preparation and application of TRAb. The invention provides an antibody, application of the antibody in preparation of a TRAb detection kit, a reagent and the kit. The TSHR recombinant mouse monoclonal antibody is obtained through screening by means of a hybridoma screening technology, and experiments prove that the monoclonal antibody is high in specificity and detection sensitivity and plays an important role in later application and clinical diagnosis. In addition, the antibody has high consistency with a liquid-mass result. Through identification, when the monoclonal antibody is used for repeated detection for multiple times, the stability is good, and the accuracy is high.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to antibodies and applications thereof. Background Art

[0002] Human thyroid-stimulating hormone receptor (hTSHR) is mainly present on the membrane of thyroid follicular epithelial cells. TSHR is a member of the G protein-coupled receptor family. It is essentially a glycoprotein composed of 764 amino acids with a molecular weight of about 85 KD. It is divided into three parts: the extracellular region, the transmembrane region, and the intracellular region. TSHR can act as an autoantigen and bind to thyroid stimulating antibodies (TSAb) to produce a stimulating reaction similar to TSH, which ultimately leads to the loss of thyroid self-immune tolerance, the production and release of excessive thyroid hormones, and clinical manifestations of hyperthyroidism such as palpitations, sweating, and hyperphagia.

[0003] TRAb is one of the important causes of hyperthyroidism and recurrence of hyperthyroidism in patients with Graves' disease. Since TRAb is an IgG antibody, it can pass through the placenta and stimulate the fetal thyroid gland to cause neonatal hyperthyroidism. Monitoring serum TRAb levels has important clinical value for the diagnosis, differential diagnosis, efficacy observation, and prognosis of thyroid diseases. At the same time, thyrotropin receptor antibodies (TRAb) are an important factor in the onset of toxic diffuse goiter (Graves' disease, GD). It has become one of the important diagnostic indicators of GD and can reflect the activity level of GD. It has important clinical significance for the prognosis of GD, the prediction of recurrence, and the identification of high-risk populations. Therefore, it is of great practical significance to provide antibodies that can quickly and sensitively detect the concentration of TRAb in patient serum. Summary of the invention

[0004] In view of this, the present invention provides antibodies and applications thereof, wherein the recombinant antibodies can rapidly and sensitively detect the concentration of TRAb in patient serum.

[0005] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0006] The present invention provides an antibody, the heavy chain variable region of which has:

[0007] (1) the nucleotide sequence shown in SEQ ID NO: 1; or

[0008] (2) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as (1); or

[0009] (3) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (1) or (2);

[0010] Its light chain variable region has:

[0011] (4) the amino acid sequence shown in SEQ ID NO: 2; or

[0012] (5) An amino acid sequence obtained by substituting, deleting or adding one or more residues of the amino acid sequence shown in (4), and having the same or similar function as (4); or

[0013] (6) an amino acid sequence having at least 95% homology to the amino acid sequence shown in (4) or (5);

[0014] The plurality is 2 to 10.

[0015] The present invention also provides a nucleic acid molecule having a nucleotide sequence encoding the above antibody.

[0016] In some specific embodiments of the present invention, the above-mentioned nucleic acid molecule has:

[0017] (7) the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4; or

[0018] (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or

[0019] (9) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (7) or (8);

[0020] The plurality is 2 to 10.

[0021] The present invention also provides an expression vector having:

[0022] (7) the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4; or

[0023] (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or

[0024] (9) A nucleotide sequence having at least 90% homology to the nucleotide sequence shown in (7) or (8);

[0025] The plurality is 2 to 30.

[0026] The present invention also provides a cell having:

[0027] (I), the above antibodies; or

[0028] (II), the above-mentioned nucleic acid molecule; or

[0029] (III) the above-mentioned expression vector.

[0030] The present invention also provides the use of any of the following in the preparation of a reagent or kit for detecting TRAb:

[0031] (a) the above-mentioned antibodies;

[0032] (b) the above-mentioned nucleic acid molecule;

[0033] (c) the above-mentioned expression vector;

[0034] (d) The above cells.

[0035] The present invention also provides the use of any of the following in the preparation of a reagent or kit for detecting TSHR:

[0036] (a) the above-mentioned antibodies;

[0037] (b) the above-mentioned nucleic acid molecule;

[0038] (c) the above-mentioned expression vector;

[0039] (d) The above cells.

[0040] The present invention also provides a reagent, including an acceptable auxiliary material or adjuvant, and any of the following items:

[0041] (a) the above-mentioned antibodies;

[0042] (b) the above-mentioned nucleic acid molecule;

[0043] (c) the above-mentioned expression vector;

[0044] (d) The above cells.

[0045] The present invention also provides a kit, comprising acceptable adjuvants or auxiliary agents, and any of the following items:

[0046] (a) the above-mentioned antibodies;

[0047] (b) the above-mentioned nucleic acid molecule;

[0048] (c) the above-mentioned expression vector;

[0049] (d) the above cells;

[0050] (e) the above reagents.

[0051] The present invention also provides a method for detecting TRAb, comprising:

[0052] (A) Detection of TRAb based on the above antibodies; or

[0053] (B), expressing the above nucleic acid molecule to obtain an antibody, and detecting TRAb based on the antibody; or

[0054] (C), expressing the above expression vector to obtain an antibody, and detecting TRAb based on the antibody; or

[0055] (D), culturing the above cells to obtain antibodies, and detecting TRAb based on the antibodies; or

[0056] (E) Detection of TRAb based on the above reagents; or

[0057] (F) Detection of TRAb based on the above kit.

[0058] The antibodies of the present invention have the following effects:

[0059] The present invention utilizes hybridoma screening technology to screen and obtain the TSHR recombinant mouse monoclonal antibody of the present invention. Experiments have shown that the monoclonal antibody has strong specificity and high detection sensitivity, and plays an important role in later applications and clinical diagnosis. In addition, the antibody has high consistency with the results of liquid quality control. It has been identified that the monoclonal antibody has good stability and high accuracy when repeatedly tested. BRIEF DESCRIPTION OF THE DRAWINGS

[0060] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0061] Figure 1 Shown is the SDS-PAGE electrophoresis diagram of TSHR antibody purification;

[0062] Figure 2 Shows HPLC analysis of TSHR antibodies;

[0063] Figure 3 The correlation between the Roche kit and the RSR+self-produced TSHR enzyme-labeled antibody kit is shown;

[0064] Figure 4 The correlation between Roche kit and self-produced kit is shown. DETAILED DESCRIPTION

[0065] The present invention discloses antibodies and their applications. Those skilled in the art can refer to the contents of this article and appropriately improve the process parameters to achieve them. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0066] The present invention relates to the field of antibody technology, and in particular to the preparation and application of thyroid stimulating hormone receptor monoclonal antibodies. The antibody preparation of the present invention mainly comprises the following steps:

[0067] ① Antigen preparation; ② Animal immunization; ③ 40 μL microfluidic electrofusion chip for plasma cell and SP2 / 0 cell fusion, including spleen cell preparation and feeder layer preparation, pre-fusion preparation; ④ Hybridoma cell screening and cloning; ⑤ Monoclonal antibody expansion production; ⑥ Monoclonal antibody type and subtype and ascites titer determination. In some embodiments, it also includes ⑦ enzyme-cleaved antibody preparation.

[0068] The present invention uses TSHR coupled carrier protein to prepare artificial antigens as immunogens, immunizes experimental animals, and then uses hybridoma cell screening technology to screen and obtain the TSHR recombinant mouse monoclonal antibody of the present invention, whose heavy chain variable region has the amino acid sequence shown in SEQ ID NO: 1; and its light chain variable region has the amino acid sequence shown in SEQ ID NO: 2.

[0069] In some embodiments, the method for preparing F(ab)2' antibody by enzymatic cleavage of the present invention comprises the following steps: 1) using pepsin or papain as the protease; 2) dissolving the protease and adding it to the antibody for overnight reaction; 3) separating and purifying the F(ab)2' antibody after enzymatic cleavage to obtain the F(ab)2' antibody.

[0070] The TSHR recombinant mouse monoclonal antibody provided by the present invention has a heavy chain variable region having an amino acid sequence as shown in SEQ ID NO:1; and a light chain variable region having an amino acid sequence as shown in SEQ ID NO:2.

[0071] The monoclonal antibody of the present invention further comprises a constant region, wherein the constant region of the heavy chain is rabbit IgG1; and the constant region of the light chain is of κ type.

[0072] The present invention also provides an immunogen encoding the monoclonal antibody.

[0073] Wherein, the immunogen encoding the monoclonal antibody is TSHR coupled carrier protein.

[0074] The carrier protein is preferably hemocyanin (KLH), bovine serum albumin (BSA), or ovalbumin (OVA).

[0075] The present invention also provides nucleotides encoding the monoclonal antibody.

[0076] The present invention provides a nucleotide sequence encoding the heavy chain of the monoclonal antibody.

[0077] The present invention provides a nucleotide sequence encoding the monoclonal antibody light chain.

[0078] The present invention provides a nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody.

[0079] The nucleotide sequence encoding the heavy chain variable region of the monoclonal antibody is shown in SEQ ID NO:3.

[0080] The present invention provides a nucleotide sequence encoding the light chain variable region of the monoclonal antibody.

[0081] The nucleotide sequence encoding the light chain variable region of the monoclonal antibody is shown in SEQ ID NO:4.

[0082] The present invention also provides basic steps for preparing mouse monoclonal antibodies: ① antigen preparation; ② animal immunization; ③ cell fusion, including preparation of spleen cells and feeder layer, and pre-fusion preparation; ④ hybridoma cell screening and cloning; ⑤ monoclonal antibody expansion production; ⑥ monoclonal antibody type and subtype and ascites titer determination. In some embodiments, it also includes ⑦ enzyme-cleaved antibody preparation.

[0083] In some embodiments, the present invention also provides an enzymatic antibody preparation process, 1) using pepsin or papain as the protease; 2) dissolving the protease and adding it to the antibody for overnight reaction; 3) separating and purifying the F(ab)2' antibody after enzymatic cleavage to obtain the F(ab)2' antibody.

[0084] The magnetic microparticle chemiluminescence method described in the present invention is to connect the prepared TRAb with fluorescein and then connect it with human TSHR to couple it to magnetic beads, and TRAb in serum and TRAb enzyme-labeled antibody compete for human TSHR antigen.

[0085] In some embodiments, the TRAb is detected by magnetic particle chemiluminescence method.

[0086] The present invention utilizes hybridoma cell screening technology to screen and obtain the TRAb mouse monoclonal antibody of the present invention, mainly by fusing mouse cells immunized with antigens with mouse myeloma cells. Under the action of a selective culture medium, only hybrid cells fused with B cells and myeloma cells have the ability to proliferate continuously, forming cells that simultaneously have the two characteristics of antibody secretion function and maintaining cell immortality.

[0087] The present invention provides an electrofusion technology, which mainly uses a commercial BTX 50 μL electrofusion cell to mix sorted plasma cells with SP2 / 0 cells in a 1:1 ratio, with a total cell number of 2×10 5 Electrofusion was performed. Electrofusion was divided into three stages: queuing stage, fusion stage, and repair stage. In the queuing stage, the voltage was set to 30 V, the time was 40 s, and the frequency was 1.5 MHz; in the fusion stage, the voltage was set to 65 V, the electroporation was performed once, and the time was 30 s; in the repair stage, the voltage was set to 30 V and gradually decreased to 5 V, and the time was 30 s.

[0088] The TSHR recombinant mouse monoclonal antibody and the conjugate of the present invention are used in preparing products for detecting TRAb levels.

[0089] The present invention also provides a kit, which comprises the TSHR recombinant mouse monoclonal antibody of the present invention, the enzyme conjugate and magnetic beads.

[0090] The kit of the present invention is suitable for the magnetic microparticle chemiluminescence of TSHR. The detection principle is that the magnetic beads are coated with TSHR antibodies connected with fluorescein FITC, and then combined with Human-TSHR, TRAb-HRP and the detected antibodies in the serum compete for the Human-TSHR antigen on the magnetic beads.

[0091] The TSHR recombinant mouse monoclonal antibody provided by the invention is suitable for immunological detection of TSHR.

[0092] In some embodiments, the TSHR is detected by magnetic particle chemiluminescence.

[0093] The antibody of the present invention is mainly obtained by hybridoma screening technology, the basic principle of which is to fuse two cells while maintaining the main characteristics of both. The two cells are mouse cells immunized with antigens and mouse myeloma cells. The main characteristics of spleen lymphocytes are their antibody secretion function and ability to grow in selective culture medium, while mouse myeloma cells can divide and proliferate indefinitely under culture conditions, i.e., so-called immortality. Such hybrid cells are called hybridoma cells.

[0094] The sequence information involved in the present invention is as follows:

[0095] The amino acid sequence of the heavy chain variable region of the TSHR recombinant mouse monoclonal antibody of the present invention is:

[0096] QEQLVESGGGLVQPGGSLKLSCKGSEIDFNSYGISWVRQAPGKGLEWIGYIDPKFGTKFYANWVNGRFTISRHNAQNTLYLQLNSLTDADTATYFCVRDRVYYSDAGPGYPYATGLGMDLWGPGTLVTVSS (SEQ ID NO: 1);

[0097] The amino acid sequence of the light chain variable region of the TSHR recombinant mouse monoclonal antibody of the present invention is:

[0098] AAVLTQTPASVSEPVGGTVTINCQASQSISNYISWYQQKPGQRPKLLIYQSSKLASGVPSRFEGSGSGTHFTLTINDLECADAATYYCQSDYGSWSLSYDNTFGGGTEVVVK (SEQ ID NO: 2);

[0099] The nucleotide sequence of the heavy chain variable region of the TSHR recombinant mouse monoclonal antibody of the present invention is:

[0100] CAGGAGCAGCTGGTGGAGTCCGGGGGAGGCCTGGTCCAGCCTGGGGGATCCCTGAAACTCTCCTGCAAAGGCTCTGAAATCGACTTTAATAGTTATGGCATTAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGATATATTGACCCTAAATTTGGTACCAAATTCTACGCGAACTGGGTGAATGGC CGATTCACCATTCCAGGCACAACGCCCAGAACACACTTTATTTGCAACTGAACAGTCTGACAGACGCGGACACGGCCACATATTTCTGTGTGAGAGATCGGGTTTATTATAGTGATGCTGGTCCTGGTTATCCTTATGCTACTGGGCTCGGCATGGACCTCTGGGGCCCAGGGACCCTCGTCACCGTCTCTTCA (SEQ ID NO:3)

[0101] The nucleotide sequence of the light chain variable region of the TSHR recombinant mouse monoclonal antibody of the present invention is:

[0102] GCAGCCGTGCTGACCCAGACTCCAGCCTCCGTGTCTGAACCTGTGGGAGGCACAGTCACCATCAATTGCCAGGCCAGTCAGAGCATTAGTAATTATATATCTTGGTATCAGCAGAAACCAGGGCAGCGTCCCAAGCTCCTGATCTACCAGTCATCCAAACTGGCATCTGG GGTCCCATCGCGATTCGAAGGCAGTGGATCTGGGACACATTTCACTCTCACCATCAACGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAAGCGATTATGGTAGTTGGAGTCTTAGCTATGATAATACTTTTGGCGGAGGGACCGAGGTGGTCGTCAAA (SEQ ID NO:4).

[0103] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.

[0104] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.

[0105] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.

[0106] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.

[0107] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values ​​and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.

[0108] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0109] The present invention will be further described below in conjunction with embodiments:

[0110] Example 1

[0111] 1. Animals immunized with recombinant immunogens:

[0112] Five 6-week-old Balb / c mice were immunized with the prepared antigen TSHR-KLH. For the first immunization, the mice were mixed with an equal volume of Freund's complete adjuvant and fully emulsified. The mice were inoculated at multiple points subcutaneously, and the antigen dose was 100 μg / mouse. The second immunization was 3 weeks later, and the same dose of antigen treated with Freund's incomplete adjuvant was injected. The antigen dose was 50 μg / mouse. The third immunization was performed three weeks later, with an inoculation dose of 50 μg / mouse. The antigen was injected once a month thereafter, and the inoculation dose was 50 μg / mouse. After the third immunization, the mouse tail vein serum can be taken for titer detection. When the fusion requirements are met, 3 days before cell fusion, the TSHR-KLH protein without adjuvant is injected intraperitoneally for booster immunization. Then the mouse spleen can be taken for cell fusion.

[0113] 2. Antiserum titer detection

[0114] Prepare the test plate, add TSHR-BSA as the detection source to 0.05 mol / L CB (pH 9.6) coating buffer, and the coating concentration is 0.625 μg / ml. The test serum is diluted from 1:200, 50 μL / well, and the unimmunized mouse serum control is set at the same time, incubated at 37℃ for 30 min; wash 5 times with PBST, pat dry, add the working concentration of anti-mouse IgG enzyme conjugate, 50 μL / well, incubate at 37℃ for 30 min; wash 5 times with PBST, pat dry, add the colorimetric agent and substrate solution, 50 μL / well each, add the stop solution 10 minutes later, 50 μL / well, and measure the signal value. The test results are shown in Table 1. After the titer reaches 1:64000, the last booster immunization is carried out, and the animals are killed three days later to extract spleen cells.

[0115] Table 1: TSHR mouse titer test results

[0116]

[0117] Conclusion: The titer of serum of mice after 5 immunizations all reached 1 / 256, among which the titer of 5# mice was the highest and cell fusion could be performed.

[0118] (III) 50 μL microfluidic electrofusion chip for plasma cell and SP2 / 0 cell fusion

[0119] 1) After isolating SPF mouse spleen cells, mouse myeloma Sp2 / 0 cells and spleen cells were mixed at a ratio of 1:3;

[0120] 2) Use a commercial BTX 40 μL electrofusion pool to mix the sorted rare plasma cells with SP2 / 0 cells at a 1:1 ratio and adjust the total number of cells to 1×10 7 indivual;

[0121] 3) Determine the optimal queuing voltage for electrofusion: set 6 queuing voltages, that is, the alternating current (AC) field strengths are designed to be 15 V, 20 V, 25 V, 30 V, 35 V, and 40 V, respectively, the time is set to 30 s, the AC field frequency is 2 MHz, and the AC field duration is 20 seconds. Observe the arrangement of cells under a microscope;

[0122] 4) Use two DC pulses, the DC pulse voltage (DC) is designed to be 400 V and 800 V respectively, and the DC pulse voltage is applied for 0.5 seconds. After the last pulse, use AC voltage of 50 V, 0.8 MHz, and last for 7 seconds;

[0123] 5) After fusion, transfer the cell suspension from the fusion chamber to pre-warmed HAT medium (Sigma, Catalog No.: H0262-10VL) and adjust the cell number to 5 × 10 5 100 μL per well was added to a 96-well plate containing primary cells from peritoneal fluid of SPF mice as feeder cells. 2 Medium cultivation;

[0124] 6) After 6 days of culture, record the number of hybridoma cell colonies; after 7 to 8 days of culture, take the cell culture supernatant to screen for positive hybridoma cells.

[0125] 4. Screening of hybridoma cell lines

[0126] 1) Return the TSHR-BSA test plate and HRP-goat anti-mouse secondary antibody enzyme to room temperature, and label the test plate rack and strips.

[0127] 2) Number the cell culture plates and add the cell culture supernatant to the corresponding test plates in sequence. Add DMEM (20% FBS) to the negative control and TSHR antibody (enzyme diluted to 5 μg / ml) to the positive control, 50 μL / well, react at 37℃ for 30 min, wash the plates 5 times with PBST and pat dry.

[0128] 3) Add HRP-goat anti-mouse IgG+IgM 1 / 4K to each well, 50 μL / well, react at 37°C for 30 min, wash the plate 5 times with PBST and pat dry.

[0129] 4) Add equal volumes of mixed ELISA substrate solution + color development solution to each well, 100 μL / well, react at room temperature for 10 min, add stop solution, 50 μL / well, to terminate the reaction.

[0130] 5) Use an ELISA reader to detect the OD value at a wavelength of 450 nm, and select the positive wells with an OD 450 nm value greater than 0.5 for full-volume medium replacement and retest.

[0131] 6) Select the positive wells with OD 450 nm values ​​greater than 0.5 after repeated testing and perform subcloning more than three times. Table 2 shows the ELISA test results after three screenings.

[0132] Table 2

[0133]

[0134] 5. In-depth evaluation of antibodies produced by five cell lines

[0135] Experimental steps:

[0136] 1) Return the TSHR-BSA test plate and HRP-goat anti-mouse secondary antibody enzyme to room temperature, and mark the test plate rack and strips;

[0137] 2) Add the culture supernatants of the above five cell lines to the corresponding test plates, add calibrators at the same time, add DMEM (20% FBS) to the negative control, and add TSHR antibody (enzyme diluted to 5 μg / ml) to the positive control, 50 μL / well, react at 37℃ for 30 minutes, wash the plate 5 times with PBST and pat dry;

[0138] 3) Add HRP-goat anti-mouse IgG+IgM 1 / 4K to each well, 50 μL / well, react at 37°C for 30 min, wash the plate 5 times with PBST and pat dry;

[0139] 4) Add equal volumes of mixed luminescent substrate A and luminescent substrate B to each well, 100 μL / well, and react at room temperature in the dark for 5 minutes for detection.

[0140] (VI) Experimental results:

[0141] Table 3

[0142]

[0143] Conclusion: The titer and gradient of antibody No. 5 are optimal.

[0144] 7. Ascites production and antibody preparation

[0145] The No. 5 cell line was selected and inoculated into 10-week-old Balb / c mice, and 0.5 mL of Freund's incomplete adjuvant was injected intraperitoneally. After 7 days, 10 6 After one week, the abdomen of the mouse swells and fluctuates when touched, indicating the presence of ascites in the abdominal cavity. At this time, the ascites can be collected and the antibody can be purified by protein A affinity chromatography, and its purity can be identified by SDS-PAGE electrophoresis. Figure 1 Electropherogram and Figure 2 HPLC results showed that the antibody purity was >80%, the batch-to-batch consistency was good, the enzyme-labeled antibody peak shape was consistent, and the process repeatability was good.

[0146] 8. Antibody SPA purification and SDS-PAGE identification column balance

[0147] Set the flow rate to 6.4 mL / min, and rinse the column with 0.02 mol / L PBS pH 7.4 equilibration buffer. Set the flow rate to 3.8 mL / min for sample loading and purification. Take 10 μL of the sample in the flow-through tube and add it to 200 μL of G250 dye solution. When it turns blue, put the flow-through tube into a 250 mL conical flask to start collecting the flow-through. Re-equilibrate: Set the flow rate to 6.4 mL / min, and rinse the column again with 0.02 mol / L PBS pH 7.4 equilibration buffer until no protein flows through. Dissociate: Place 10 4 mL centrifuge tubes on the dissociation tube rack, add 200 μL of 1 mol / L Tris pH 8.5 to each tube, set the constant flow pump to set the flow rate to 6.4 mL / min, and dissociate the target protein with 0.2 mol / L Gly+0.15 mol / L NaCl pH 2.7 dissociate buffer, and take 10 μL of the sample from the flow-through tube and add it to 200 The collected proteins were combined and tested by SDS-PAGE to obtain the self-produced TSHR antibody. After sequencing, the heavy chain variable region had the amino acid sequence shown in SEQ ID NO:1; the light chain variable region had the amino acid sequence shown in SEQ ID NO:2; the corresponding nucleotide sequences were shown in SEQ ID NO:3 and SEQ ID NO:4, respectively.

[0148] Example 2: Gradient test

[0149] The self-produced TSHR antibody described in Example 1 was labeled with horseradish peroxidase to obtain a self-produced TSHR enzyme-labeled antibody. The self-produced TSHR enzyme-labeled antibody (using ordinary enzyme dilution, 0.01 mol PBS + 0.5% BSA, 1 / 4K) was used to replace the RSR kit (thyroid stimulating hormone receptor antibody detection kit, manufacturer RSR Ltd, item number TCT / 60 or 100) enzyme-labeled antibody, and the control used the RSR full set of reagents. The results are shown in Table 4. The gradient of the self-produced enzyme-labeled antibody between different standards is consistent with the control.

[0150] Table 4: TSHR enzyme-labeled antibody replaces RSR enzyme-labeled antibody

[0151]

[0152] Example 3: Correlation test

[0153] Twenty clinical samples were tested using the Roche kit, the RSR kit + self-produced TSHR enzyme-labeled antibody (self-produced TSHR enzyme-labeled antibody was used to replace the original enzyme-labeled antibody in the RSR kit), and the self-produced kit.

[0154] The self-produced kit includes:

[0155] 1) Magnetic microparticle suspension (coated with FITC antibody);

[0156] 2) Antigen reagent (lyophilized, FITC-labeled anti-human TSH receptor mouse monoclonal antibody-human TSH receptor complex);

[0157] 3) Antigen reagent buffer;

[0158] 4) Enzyme conjugate (containing self-produced TSHR enzyme-labeled antibody) 1 / 2K;

[0159] 5) Assay diluent (buffer containing protein);

[0160] 6) Calibrator (including recombinant TSH receptor antibody).

[0161] Experimental steps: After preparing the test sample and placing it correctly, click the start button to start the sample detection program. The instrument performs the following operations:

[0162] 1) Transfer the sample rack to the sample suction position and load the reaction container to the sample addition position;

[0163] 2) Perform the sample testing procedure and complete the dispensing of 100 μL sample, 20 μL reconstituted antigen reagent, and 50 μL analytical diluent;

[0164] 3) Mix the reaction solution and incubate for 17 min;

[0165] 4) Complete the injection of 20 μL magnetic particle suspension and 50 μL enzyme conjugate;

[0166] 5) Mix the reaction solution and incubate for 15 min;

[0167] 6) After the incubation is completed, use a cleaning solution to clean and separate the reaction solution;

[0168] 7) Complete the injection of 50 μL substrate A and 50 μL substrate B;

[0169] 8) Mix the reaction solution and detect the luminescence intensity.

[0170] The results are shown in Table 5. Figure 3 , Figure 4 shown.

[0171] Table 5: Clinical evaluation

[0172]

[0173] Conclusion: The correlation between the RSR ELISA plate and the self-produced TSHR enzyme-labeled antibody and Roche is more than 99%; the correlation between the self-produced kit and the Roche test is more than 99%.

[0174] Example 4: Specificity Assessment

[0175] Clinical samples were tested using the RSR kit and the self-produced kit shown in Example 2, and the clinical samples included: PQ1 (TRAb content: 1.83 pg / ml), PQ2 (TRAb content: 6.83 pg / ml), PQ3 (TRAb content: 19.76 pg / ml), PQ4 (TRAb content: 29.45) and PQ5 (TRAb content: 35.86).

[0176] Experimental steps: After preparing the test sample and placing it correctly, click the start button to start the sample detection program. The instrument performs the following operations:

[0177] 1) Transfer the sample rack to the sample suction position and load the reaction container to the sample addition position;

[0178] 2) Perform the sample testing procedure and complete the dispensing of 100 μL sample, 20 μL reconstituted antigen reagent, and 50 μL analytical diluent;

[0179] 3) Mix the reaction solution and incubate for 17 min;

[0180] 4) Complete the injection of 20 μL magnetic particle suspension and 50 μL enzyme conjugate;

[0181] 5) Mix the reaction solution and incubate for 15 min;

[0182] 6) After the incubation is completed, use a cleaning solution to clean and separate the reaction solution;

[0183] 7) Complete the injection of 50 μL substrate A and 50 μL substrate B;

[0184] 8) Mix the reaction solution and detect the luminescence intensity.

[0185] The results are shown in Table 6.

[0186] Table 6

[0187]

[0188] Conclusion: Gradient samples were evaluated simultaneously with RSR, and the results showed that gradient had more advantages.

[0189] Example 5: Precision Assessment

[0190] The samples were tested using the RSR kit and the self-produced kit shown in Example 2. The samples included: Q1, Q2, Q3, and the main components were human serum + TRAb, wherein the TRAb content was: Q1: 0.95 pg / ml; Q2: 7.58 mg / ml; Q3: 18.93 mg / ml).

[0191] Each sample was tested in 10 replicates, and the experimental steps were the same as in Example 1. The results are shown in Table 7.

[0192] Table 7

[0193]

[0194] Conclusion: From the data, we can see that the mutation rate is within 5%.

[0195] Summary: The above data show that the antibodies prepared in this application have better performance than the RSR kit, and have good specificity and precision.

[0196] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. An antibody, characterized in that include: The heavy chain variable region has: (1) the nucleotide sequence shown in SEQ ID NO: 1; or (2) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as (1); or (3) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (1) or (2); The light chain variable region has: (4) the amino acid sequence shown in SEQ ID NO: 2; or (5) An amino acid sequence obtained by substituting, deleting or adding one or more residues of the amino acid sequence shown in (4), and having the same or similar function as (4); or (6) an amino acid sequence having at least 95% homology to the amino acid sequence shown in (4) or (5); The plurality is 2 to 10.

2. A nucleic acid molecule having a nucleotide sequence encoding the antibody according to claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that have: (7) the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4; or (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or (9) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (7) or (8); The plurality is 2 to 10.

4. An expression vector, characterized in that have: (7) the nucleotide sequence shown in SEQ ID NO: 3 and / or SEQ ID NO: 4; or (8) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as (7); or (9) A nucleotide sequence having at least 95% homology to the nucleotide sequence shown in (7) or (8); The plurality is 2 to 10.

5. A cell, characterized in that have: (I), the antibody according to claim 1; or (II), a nucleic acid molecule according to claim 2 or 3; or (III) The expression vector according to claim 4.

6. Use of any of the following in the preparation of a reagent or kit for detecting TRAb: (a) The antibody according to claim 1; (b) a nucleic acid molecule according to claim 2 or 3; (c) The expression vector according to claim 4; (d) The cell according to claim 5.

7. A reagent, characterized in that Include acceptable excipients or adjuvants, and any of the following: (a) The antibody according to claim 1; (b) a nucleic acid molecule according to claim 2 or 3; (c) The expression vector according to claim 4; (d) The cell according to claim 5.

8. A kit, characterized in that Include acceptable excipients or adjuvants, and any of the following: (a) The antibody according to claim 1; (b) a nucleic acid molecule according to claim 2 or 3; (c) The expression vector according to claim 4; (d) The cell according to claim 5; (e) The reagent according to claim 7.

9. A method for detecting TRAb, characterized in that: include: (A) Detecting TRAb based on the antibody according to claim 1; or (B), expressing the nucleic acid molecule according to claim 2 or 3, obtaining an antibody, and detecting TRAb based on the antibody; or (C) expressing the expression vector according to claim 4 to obtain an antibody, and detecting TRAb based on the antibody; or (D) culturing the cell according to claim 5 to obtain an antibody, and detecting TRAb based on the antibody; or (E) detecting TRAb based on the reagent according to claim 7; or (F) Detecting TRAb based on the kit according to claim 8.